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Introduction
Blood transfusion from healthy donors is a very widely 
used medical therapy. It has been estimated that about 40% 
of critically ill adult patients receive at least one unit of 
packed red blood cells (RBC) while in an intensive care 
unit, with a mean of five units per patient1,2. Although RBC 
transfusion can be considered a life-saving therapy, this 
procedure is not without risk. In the last 10 years a growing 
body of evidence has indicated that RBC transfusion can 
be associated with adverse clinical outcomes including 
infections, multiple organ failure and death, particularly in 
compromised patients3,4. Recently, it was suggested that a 
large part of all these side effects could be associated with 
prolonged storage of the RBC prior to their transfusion5,6. 
Background. During storage, red blood cells (RBC) undergo chemical and biochemical changes 
referred to as "storage lesions". These events determine the loss of RBC integrity, resulting in lysis 
and release of microparticles. There is growing evidence of the clinical importance of microparticles 
and their role in blood transfusion-related side effects and pathogen transmission. Flow cytometry is 
currently one of the most common techniques used to quantify and characterise microparticles. Here 
we propose multiparametric staining to monitor and quantify the dynamic release of microparticles 
by stored human RBC.
Material and methods. RBC units (n=10) were stored under blood bank conditions for up to 
42 days. Samples were tested at different time points to detect microparticles and determine the 
haemolysis rate (HR%). Microparticles were identified by flow cytometry combining carboxyfluorescein 
diacetate succinimidyl ester (CFSE) dye, ann xin V and anti-glycophorin A antibody. 
Results. We demonstrated that CFSE can be successfully used to label closed vesicles with an 
intact membrane. The combination of CFSE and glycophorin A antibody was effective for monitoring 
and quantifying the dynamic release of microparticles from RBC during storage. Double staining 
with CFSE/glycophorin A was a more precise approach, increasing vesicle detection up to 4.7-fold vs 
the use of glycophorin A/annexin V alone. Moreover, at all the time points tested, we found a robust 
correlation (R=0.625; p=0.0001) between HR% and number of microparticles detected. 
Discussion. Multiparametric staining, based on a combination of CFSE, glycophorin A antibody 
and annexin V, was able to detect, characterise and monitor the release of microparticles from RBC 
units during storage, providing a sensitive approach to labelling and identifying microparticles for 
transfusion medicine and, more broadly, for cell-based therapies.
Keywords: microparticles, CFSE, red blood cells, flow cytometry.
Under standard blood banking conditions, RBC 
undergo progressive structural and biochemical changes 
commonly referred to as "storage lesions"7. This process 
includes alterations in pH, lactate, nitric oxide and 
ATP levels, as well as loss of biconcave shape and 
RBC lysis (haemolysis)8. Moreover, attention has been 
given to the spontaneous release of microparticles, a 
physiological step of erythrocyte senescence that may be 
enhanced by various stimuli occurring during storage9,10. 
Microparticles are small phospholipid vesicles of less 
than 1 μm in size, containing a subset of proteins 
derived from their parent cell s11,12. These cellular 
elements have long been considered as cell debris with 
no biological functions13. Recently, however, several 
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studies have demonstrated that microparticles play roles 
in intercellular communication and are involved in a broad 
spectrum of pathological conditions such as thrombosis, 
cardiovascular disease, diabetes and infections14-20. It 
has also been reported that the number of microparticles 
in RBC units gradually increases with storage time, 
suggesting that these microparticles might contribute to 
adverse transfusion reactions. It is, therefore, important 
to establish novel approaches to careful monitoring and 
precise quantification of the release of microparticles in 
RBC units9,21,22.
Although flow cytometry procedures have been 
reported, currently there is no standard method to 
analyse microparticles in blood samples23-25. It has been 
established that RBC microparticles can be identified by 
flow cytometry thanks to their expression of glycophorin 
A, a protein uniquely expressed by erythrocytes, and 
phosphatidylserine26-28. Phosphatidylserine is normally 
exposed on the inner leaflet of the cell membrane; 
however, during apoptosis it is exposed on the outer 
side of the membrane, becoming detectable by annexin 
V binding29. Although widely used, this approach may 
generate some errors because of staining of cellular 
fragments and debris, in addition to microparticles. 
Moreover it has been recently demonstrated that not all 
microparticles express phosphatidylserine22,26,28.
In this study, we investigated the dynamic 
release of microparticles by stored RBC using a new 
multiparametric approach based on carboxyfluorescein 
succinimidyl ester (CFSE) dye in combination with 
anti-glycophorin A antibody and annexin V. We 
demonstrate that the inclusion of CFSE dye in 
combination with anti-glycophorin A antibody and 
annexin V enables clear identification of closed vesicles, 
providing an effective strategy for visualising and 
quantifying microparticles in biological samples.
Materials and methods
Red blood cell preparation
Ten randomly selected RBC units were supplied by 
the Division of Transfusion Medicine at the University 
Hospital of Modena upon approved agreement 
n. 0030164/0003928. Only units that did not satisfy 
quality criteria for transfusion, because of elevated 
liver enzymes or leucocyte number, were used for this 
study. Whole blood (450 mL±10%) was collected from 
healthy volunteer donors into blood bags (Fresenius 
Kabi, Zverinek, Czech Republic) containing CPD 
anticoagulant (63 mL). After centrifugation in a 
SorvallTM RC12BP (Thermo Scientific, Waltham, 
MA, USA) centrifuge at 4544g for 10 minutes at room 
temperature, plasma and buffy coat were separated and 
the RBC were suspended in SAG-M additive solution 
(100 mL) and leucodepleted by filtration. RBC units 
were stored under standard blood bank conditions 
(4±2 °C) up to day 42. Samples were collected by a 
sterile sampling device on days 0, 10, 20, 30 and 42 
and were tested for the presence of microparticles 
and underwent standard RBC quality controls. RBC 
haematocrit and total haemoglobin were measured 
using a CeLL-DYN Ruby haematology analyser 
(Abbot Diagnostics, Illinois, IL, USA). Extracellular 
haemoglobin concentration was determined by a 
HemoCue Plasma/Low Hb System (HemoCue AB, 
Ängelholm, Sweden) after sample centrifugation at 
3,000 rpm for 5 minutes. The percentage of haemolysis 
was calculated using the following formula:
Haemolysis rate %= 
fHb
mg/dL
×(1-Hct/100)
         (Hb
g/dL
×1,000)×10030
Flow cytometry 
Ten microlitres of RBC concentrate were stained 
for 30 minutes on ice in 100 μL binding buffer (BD 
Pharmingen, San Diego, CA, USA) containing 5 μL 
phycoerythrin anti-human glycophorin A (CD235a) 
antibody (BD Pharmingen), 2 μL CFSE (Molecular 
Probe, Eugene, OR, USA) and 10 μL annexin 
V-allophycocyanin (BD Pharmingen). The optimal 
concentration was experimentally determined for each 
antibody or dye by titration experiments. After staining, 
samples were diluted with binding buffer to reach a final 
volume of 1 mL. Using a reverse pipetting technique, 
50 μL of diluted stained sample were pipetted into a 
TruCount tube (BD Biosciences,San Jose, CA, USA) 
to which 300 μL of binding buffer were then added. 
TruCount tubes, containing a standardised number of 
fluorescent beads, were used to quantify microparticles. 
The microparticles were detected by a FACSAria III 
flow cytometer (BD Biosciences) equipped with two 
air-cooled lasers at 488 and 633 nm wavelengths. An 
unstained sample was acquired to detect the sample 
auto-fluorescence and set the photomultiplier for all 
the considered channels; fluorescent cross-talk was 
controlled by compensation adjustment. Compensation 
settings were established by acquiring single-colour 
stained tubes. Collected data were analysed by Diva 
software (BD Biosciences). Microparticles were 
identified by relative size; forward and side scatter 
channels (FSC and SSC) were used on a logarithmic 
scale. The setup of the FSC and SSC photomultiplier 
was calculated using background noise as the lower 
limit. The FSC photomultiplier was increased until 
the background noise filled the dots available of dot 
plots. The threshold, set on the FSC channel, was 
increased to reduce the noise progressively, in order 
to detect microparticles. To provide a reference size, 
Megamix beads (BioCytex, Marseille, France) were 
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RBC microparticle detection by CFSE
acquired with the same settings used for microparticles. 
Sample acquisition was discontinued when the number 
of TruCount beads in the relative region reached 
5,000 events. The number of microparticles per 
microlitre was calculated as follow: 
 
Statistical analyses
Data are given as mean values and represented by 
box plots. The data were subjected to one-way analysis 
of variance (ANOVA) where ANOVA assumptions 
were not violated (residual diagnostics). In other cases 
a robust algorithm for variance stabilisation (Box-Cox 
power transformation) was applied and ANOVA was 
performed on transformed data. Statistical computations 
were carried out using Minitab®16. Two-tailed t-tests 
and Pearson's tests were used when applicable. A 
p-value<0.05 was considered statistically significant.
Results
Microparticles from red blood cells can be efficiently 
labelled by CFSE 
We here targeted a common RBC marker by anti-
human glycophorin A antibody along with annexin V in 
combination with CFSE, a fluorescent dye never used 
before for the detection of RBC microparticles (Figure  1). 
CFSE has been used for years in assessing the proliferation 
of nucleated cells and to specifically label RBC with no 
evidence of toxi city31-33. Given its chemical properties we 
hypothesised that CFSE could definitively distinguish 
microparticles with intact membrane structures from 
cellular debris. In particular, we wanted to take advantage 
of the fact that CFSE passively diffuses into microparticles 
and once within the microparticles can be hydrolysed by 
intracellular esterase, becoming fluorescent and easily 
distinguishing the microparticles from cellular fragm ents34.
As shown in Figure 1, the population of microparticles 
was first identified by morphological gating according 
to their light scattering profile (Figure 1A). The 
identified vesicle population was then analysed for 
CFSE fluorescence (Figure 1B). Given the small size of 
microparticles and their reduced cytoplasmic content, the 
intensity of the CFSE signal released by microparticles 
was one logarithm lower than that observed for the RBC, 
allowing the microparticles to be clearly distinguished 
from their parental cells (Figure 1B). Subsequently, only 
CFSE-positive microparticles were investigated 
for glycophorin A expression in order to consider 
microparticles that had originated from erythrocytes 
(Figure 1C). In addition, a simultaneous comparative 
analysis of annexin V-positive elements in the 
CFSE/glycophorin A-positive population revealed that only 
a small fraction of microparticles was labelled by annexin 
V (Figure 1D). Collectively this multiparametric approach 
confirmed that the majority of RBC microparticles resulted 
negative for annexin V and revealed that CFSE can 
efficiently and selectively label microparticles, indicating 
that closed, intact vesicles containing cytoplasmic 
enzymes are able to metabolise CFSE.
CFSE/glycophorin A staining allows proper 
quantification of red blood cell-derived microparticles
Having established the protocol and the gating 
strategy, we then wanted to test them by quantifying 
microparticles in stored RBC. The microparticle 
measurements were initially performed considering all 
events included in the morphological gate according 
to a well-defined light scatter profile, illustrated in 
Figure 1A. The mean number of microparticles detected 
from day 0 (T0) to day 42 (T42) progressively increased 
from 1.17×105±0.067×105 to 2.58×105±0.34×105 
(Figure 2A; p<0.0001 by ANOVA). Since the use of a 
morphological gate alone may result in enumeration of 
non-specific microparticles, including contaminating 
cellular fragments with similar FSC and SSC values 
as those of microparticles, we combined this gate with 
double CFSE/glycophorin A labelling (Figure 2B). 
As expected, the trend in microparticle numbers was 
comparable for both the described gating strategies, 
although the absolute number of microparticles counted 
in the CFSE/glycophorin A-positive gate was lower 
(1.03×105±0.072×105 to 2.09×105±0.32×105, Figure 2B) 
than that in the morphological gate. The reason why the 
results from the morphological gate did not completely 
overlap with those from the CFSE/glycophorin 
A-positive gate was the exclusion of cellular fragments 
which were negative for CFSE staining; these fragments 
accounted from up to 19% of the events at day 42.
In addition, the analysis of microparticle number 
revealed a 2-fold increase in particles in stored 
RBC units from T0 to T42 (p<0.005 by ANOVA). 
Interestingly, a more in depth study of the microparticle 
population revealed that annexin V was able to 
detect only 27.56±3.47% of the entire population of 
CFSE/glycophorin A-positive microparticles at T0, 
while this percentage increased at T42, reaching 
34.07±1.75%. Although the mean number of annexin 
V-positive vesicles increased during RBC storage, this 
value was always significantly lower (by as much as 
4.7-fold) than the mean number of microparticles 
detected by the CFSE/glycophorin A gating strategy 
(p<0.0002 by the t-test) (Figure 2C). 
×
N. of bead 
counts per test
Sample volume(μL)
N. of events in gating 
containing  microparticles  
N. of events in absolute 
count bead region
×
Dilution 
factor
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Microparticle detection by CFSE correlates with red 
blood cell lysis during storage
RBC lysis is one of the main events occurring during 
storage and potentially gives rise to complications associated 
with blood transfusion35. We, therefore, determined the 
level of RBC lysis and correlated this with microparticle 
release (Figure 3). As already described by others, we found 
a significant increase in haemolysis rate (HR%) during 
storage (Figure 3A; p<0.001 by ANOVA)30,36. Moreover, 
we demonstrated a significant relationship (Figure 3B) 
(R=0.625; p=0.0001 by Pearson's test) between HR% and 
microparticle number, as detected by the combination of 
CSFE/glycophorin A, indicating that levels of haemolysis 
correlated with the number of microparticles detected, at 
all the time points tested. These data further underline the 
importance of precise detection of microparticles during 
storage as an indirect parameter of RBC preservation. 
Discussion
Microparticles released by RBC are usually 
identified through the use of antibodies that bind to 
glycophorin A, a protein widely expressed on the 
erythrocyte membrane, and annexin V, which binds to 
the phosphatidylserine expressed on the outer membrane 
of the microparticles26,28,37. Several groups have recently 
reported that phosphatidylserine is not expressed by all 
microparticles and its use to identify microparticles could 
largely underestimate the total number of vesicles38-40. 
The clinical importance of microparticles has been 
progressively recognised, highlighting the need to 
better characterise their biological properties and their 
influence in pathological conditions41. Although flow 
cytometry is widely used to detect microparticles, there is 
still no consensus on the protocol for sample processing 
and microparticle detection in human blood26. In this 
study, we investigated a multiparametric approach that 
could provide a more sensitive tool for the detection of 
microparticles in stored RBC samples.
Alongside the dual labelling with glycophorin A 
and annexin V, we introduced CFSE as an unexplored 
RBC microparticle marker. CFSE was developed as 
a fluorescent dye that could be used to monitor cell 
proliferation both in vitro and in vivo31,32. The CFSE 
precursor, carboxyfluorescein diacetate succinimidyl 
Figure 1 -  Gating strategy for the identification of RBC microparticles. 
 A - Side scatter (SSC) and forward scatter (FSC) parameters of RBC microparticles (MPS). The MPS region lies between background 
noise (lower limit) and RBC (upper limit). B,C - The MPS detected in the morphological gating were also double-positive for CFSE 
and glycophorin A-PE. D - In contrast, only a small fraction of CFSE+/glycophorin A+ MPS were also positive for annexin V. 
 E - TruCount fluorescent beads, as internal reference, were used to quantify the absolute number of MPS. F - Megamix beads were 
acquired with the same settings applied for MPS detection. As shown MPS are included in the 0.5 μm bead FSC size range. 
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RBC microparticle detection by CFSE
with the detection and quantification of microparticles. At 
the same time, the use of glycophorin A was fundamental 
for determining the cellular origin of the microparticles. 
The inclusion of this antibody in our multiparametric 
approach revealed the presence of microparticles 
not expressing glycophorin A. The mean amount of 
CFSE+/glycophorin A− vesicles was 11.2% and decreased 
during storage, reaching 6% by day 42. These data suggest 
the presence of contaminating microparticles derived from 
other cellular components such as leucocytes, platelets 
or endothelial cells at the time of blood collection and 
that this population is lost progressively during storage. 
In brief, the combination of CFSE and glycophorin A 
antibody was particularly effective for careful monitoring 
and quantification of the dynamic release of microparticles 
from RBC during storage. Moreover, analysis of 
microparticles using annexin V showed that only a small 
fraction of the microparticles expressed phosphatidylserine 
on the outer membrane. Thus, the use of annexin V as a 
specific marker for RBC microparticles could lead to a 
significant underestimate of the number of particles in 
blood samples. Double staining with CFSE/glycophorin 
A increases vesicle detection by up to 4.7-fold vs the 
use of glycophorin A/annexin V alone and offers a more 
sensitive approach to the identification of microparticles 
in biological samples.
While this finding requires further investigation, we 
can speculate that during early stages of RBC storage 
only a small fraction of phosphatidylserine-expressing 
microparticles is released. The sensitivity of microparticle 
detection by CFSE/glycophorin A staining is, therefore, 
significantly higher than that achieved by glycophorin 
A/annexin V. On the other hand, after longer storage, 
cellular ageing generates an increased amount of damaged 
RBC, with a consequent rise in phosphatidylserine-
expressing microparticles, which enhances annexin V 
sensitivity. RBC were not substantially affected by the 
CFSE dye used in the current setting, as demonstrated by 
an average 7.4% annexin V-positive signal in our samples. 
Although some studies indicated an increase of cell death 
and a block of proliferation using 10 μL of CFSE42, others 
have introduced up to 50 μL with no evident toxicity43. 
The difference could be due to the variety of cell types 
considered and/or to the staining protocols. The effect of 
CFSE on cellular behaviour and on emerging biological 
features does, therefore, require further investigation.
The importance of quantifying microparticles correctly 
is becoming clearer. We wanted to correlate microparticle 
levels with haemolysis induced by storage as a possible 
novel step in the quality control of preserved, blood-derived 
products. We found that the amount of microparticles 
correlates with haemolysis rate. While the explanation of 
this correlation requires further investigation, we suspect 
that it is related to the capacity of microparticles to enclose 
Figure 2 -  Quantification and characterization of microparticles 
released by RBC during storage. 
 Graphs A and B show the number of microparticles 
(MPS)/μL evaluated according to light scattered profile 
or CFSE/glycophorin A gating strategy, respectively. 
Both analyses revealed the same trend characterized 
by a statistically significant increase of MPS number 
during storage (*,**,***,****p<0.0001 by ANOVA). 
At T42 the MPS number was 2-fold higher than at T0. 
 C - CFSE/glycophorin A+/annexin V+ MPS. 
ester (CFDA-SE) is a non-fluorescent molecule, which 
can passively diffuse through cellular membranes with 
no reported toxic effects for labelled cells31,34. Once inside 
the cells, the acetate groups are removed by intracellular 
esterases resulting in a less permeable fluorescent 
molecule, which is retained within the cytoplasm for 
long periods of time. Since it has been established that 
microparticles are encircled vesicles, containing part of the 
cytoplasmic content derived from parental cells, including 
esterase enzymes, we hypothesized that CFSE could be 
used to label and detect microparticles.
Our data demonstrate that CFSE can be successfully 
employed to label closed vesicles with an intact membrane, 
allowing exclusion of cellular fragments that may interfere 
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Figure 3 -  Assessment of RBC lysis and correlation between number of microparticles and haemolysis rate of stored  RBC. 
 A - Haemolysis rate (HR%) at different time points. A significant increase of haemolysis was observed during storage, as 
expected (*,**,***,****p<0.001 by ANOVA). B - Correlation between the number of microparticles (MPS) and HR%. 
haemoglobin, which is also detected as free haemoglobin 
during the analysis, as suggested by others44.
The detection of microparticles in blood-derived 
products and their subsequent analysis may be relevant 
in clinical practice to provide further insights into 
transfusion-related side effects. Moreover, fluorescent 
labelling would allow in vitro and in vivo tracking of 
these elements, which could then be detected after 
injection into animal models. In conclusion, the use of a 
CFSE-based approach could couple microparticle 
detection and sorting, ideally enabling isolation and further 
characterisation of the biology and clinical implications of 
these still poorly explored cellular particles. 
Conclusions
In this study, we took advantage of the dynamic release 
of MPs by stored RBC to propose a multi-parametric 
approach based on CFSE labelling in combination with 
anti-Glycophorin A antibody and Annexin V aiming 
for an improved MPs detection. Our data demonstrate 
that CFSE can be successfully employed to identify 
closed vesicles characterized by intact membrane. The 
combination of CSFE/Glycophorin/Annexin V allows to 
determine the cellular origin of these elements resulting 
in a careful monitoring and quantification of their release 
during RBC storage time. The detection of MPs in blood 
derived products and their subsequent analyses may be 
relevant for clinical practice to further provide insights 
on transfusion related side effects. In addition, this 
multi-parametric staining may provide a sensitive 
approach to detect and study MPs in transfusion 
medicine and, more broadly, in cell based therapies.
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